Market Research Life Sciences Market Research Pharmaceuticals Market Research Therapeutic Area Market Research Oncology/Hematology Market Research

Non-Small Cell Lung Cancer (NSCLC): Epidemiology Forecast to 2032

Best Price Guarantee Length Publisher Published Date SKU
from $3,995 72 Pages GlobalData February, 2024 GBDT18640218
Best Price Guarantee
Price from $3,995
Length 72 Pages
Publisher GlobalData
Published Date February, 2024
SKU GBDT18640218

Non-Small Cell Lung Cancer (NSCLC): Epidemiology Forecast to 2032


Summary

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for approximately 85% of all lung cancer cases (National Cancer Institute, 2020). NSCLC begins when healthy cells that make up the lining of the lungs change and grow out of control, forming a tumor. NSCLC can begin anywhere in the lungs and can be categorized into different histological subtypes: non-squamous cell carcinomas (which includes adenocarcinoma, large cell carcinoma, and other types such as undifferentiated or not otherwise specified carcinomas) and squamous cell carcinomas (Cleveland Clinic, 2022). The exact cause of NSCLC is not known, however, the leading risk factor for lung cancer is smoking. Many people with no smoking history or exposure to harmful chemicals can develop lung cancer too, suggesting a genetic link to disease development (Cancer.Net, 2022).

Scope

The Non-Small Cell Lung Cancer report provides an overview of the risk factors, comorbidities, and global and historical epidemiological trends for NSCLC in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and urban China). The report includes a 10-year epidemiology forecast for the diagnosed incident cases of NSCLC. The diagnosed incident cases of NSCLC are segmented by age (starting at ages 18-29 years and then in 10-year age groups up to age 80 years and older), sex, stage at diagnosis (stages IA, IB, IIA, IIB, IIIA, IIIB, IIIC, and IV), and histological subtypes: non-squamous cell carcinoma, which includes adenocarcinoma, large cell carcinoma, and others; and squamous cell carcinoma). The diagnosed incident cases of non-squamous cell carcinomas and squamous cell carcinomas are further segmented by genetic mutations. Additionally, this report includes a forecast for the five-year diagnosed prevalent cases of NSCLC. This epidemiology forecast for NSCLC is supported by data obtained from country-specific oncology registries, peer-reviewed articles, and population-based studies. The forecast methodology was kept consistent across the 8MM to allow for a meaningful comparison of the forecast for diagnosed incident cases of NSCLC across these markets.

Reasons to Buy

The Non-Small Cell Lung Cancer Epidemiology series will allow you to -
Develop business strategies by understanding the trends shaping and driving the global NSCLC markets.
Quantify patient populations in the global NSCLC markets to improve product design, pricing, and launch plans.
Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for NSCLC therapeutics in each of the markets covered.
Understand magnitude of the NSCLC population by age, sex, stage at diagnosis, histology, immunotherapy biomarkers and genetic mutations.


About GlobalData
1 Non-Small Cell Lung Cancer: Executive Summary
1.1 Catalyst
1.2 Related Reports
1.3 Upcoming Reports
2 Epidemiology
2.1 Disease background
2.2 Risk factors and comorbidities
2.3 Global and historical trends
2.4 8MM forecast methodology
2.4.1 Sources
2.4.2 Forecast assumptions and methods
2.4.3 Forecast assumption and methods: diagnosed incident cases of NSCLC
2.4.4 Forecast assumptions and methods: diagnosed incident cases of NSCLC by stage at diagnosis
2.4.5 Forecast assumptions and methods: diagnosed incident cases of NSCLC by histological type
2.4.6 Forecast assumptions and methods: diagnosed incident cases of non-squamous cell carcinomas and squamous cell carcinomas by immunotherapy biomarker
2.4.7 Forecast assumptions and methods: diagnosed incident cases of non-squamous cell carcinomas and squamous cell carcinomas by genetic biomarkers
2.4.8 Forecast assumptions and methods: diagnosed incident cases of non-squamous cell carcinomas and squamous cell carcinomas by genetic biomarker
2.4.9 Forecast assumptions and methods: diagnosed incident cases of non-squamous cell carcinomas and squamous cell carcinomas by genetic biomarker
2.4.10 Forecast assumptions and methods: five-year diagnosed prevalent cases of NSCLC
2.5 Epidemiological forecast for NSCLC (2022-32)
2.5.1 Diagnosed incident cases of NSCLC
2.5.2 Age-specific diagnosed incident cases of NSCLC
2.5.3 Sex-specific diagnosed incident cases of NSCLC
2.5.4 Diagnosed incident cases of NSCLC by stage
2.5.5 Diagnosed incident cases of NSCLC by histological type
2.5.6 Diagnosed incident cases of NSCLC by immunotherapy biomarker
2.5.7 Diagnosed incident cases of non-squamous and squamous NSCLC by genomic biomarker
2.5.8 Five-year diagnosed prevalent cases of NSCLC
2.6 Discussion
2.6.1 Epidemiological forecast insight
2.6.2 COVID-19 impact
2.6.3 Limitations of the analysis
2.6.4 Strengths of the analysis
3 Appendix
3.1 Bibliography
3.2 About the Authors
3.2.1 Epidemiologist
3.2.2 Reviewers
3.2.3 Vice President of Disease Intelligence and Epidemiology
3.2.4 Global Head of Pharma Research, Analysis and Competitive Intelligence
Contact Us
List of Tables
Table 1: Summary of added and removed data types
Table 2: Summary of updated data types
Table 3: Risk factors and comorbidities for Lung Cancer
Table 4: 8MM, diagnosed incident cases of NSCLC by stage, N, both sexes, ages ≥18 years, 2022
Table 5: 8MM, diagnosed incident cases of non-squamous and squamous NSCLC by immunotherapy biomarkers, N, both sexes, ages ≥18 years, 2022
Table 6: 8MM, diagnosed incident cases of non-squamous NSCLC by genomic biomarkers, N, both sexes, ages ≥18 years, 2022
Table 7: 8MM, diagnosed incident cases of squamous NSCLC by genomic biomarkers, N, both sexes, ages ≥18 years, 2022
List of Figures
Figure 1: 8MM, diagnosed incident cases of NSCLC, both sexes, N, ages ≥18 years, 2022 and 2032
Figure 2: 8MM, five-year diagnosed prevalent cases of NSCLC, both sexes, N, ages ≥18 years, 2022 and 2032
Figure 3: 8MM, diagnosed incidence of NSCLC, men, cases per 100,000 population, ages ≥18 years, 2012-32
Figure 4: 8MM, diagnosed incidence of NSCLC, women, cases per 100,000 population, ages ≥18 years, 2012-32
Figure 5: 8MM, sources used to forecast the diagnosed incident cases of NSCLC
Figure 6: 8MM, sources used to forecast the diagnosed incident cases of NSCLC by stage at diagnosis
Figure 7: 8MM, sources used to forecast the diagnosed incident cases of NSCLC by histological type
Figure 8: 8MM, sources used to forecast the diagnosed incident cases of non-squamous cell carcinoma by PDL1, TMB, EGFR, and KRAS mutations
Figure 9: 8MM, sources used to forecast the diagnosed incident cases of non-squamous cell carcinoma by ALK, ROS1, RET, and HER2 mutations.
Figure 10: 8MM, sources used to forecast the diagnosed incident cases of non-squamous cell carcinoma by BRAF, BRAF V600E, NTRK1, and MET Exon 14 mutations.
Figure 11: 8MM, sources used to forecast the diagnosed incident cases of squamous cell carcinomas by PDL1, TMB, EGFR, and KRAS mutations.
Figure 12: 8MM, sources used to forecast the diagnosed incident cases of squamous cell carcinomas by ALK, ROS1, RET, and HER2 mutations.
Figure 13: 8MM, sources used to forecast the five-year diagnosed prevalent cases of NSCLC in the 8MM.
Figure 14: 8MM, diagnosed incident cases of NSCLC, N, both sexes, ages ≥18 years, 2022
Figure 15: 8MM, diagnosed incident cases of NSCLC by age, N, both sexes, 2022
Figure 16: 8MM, diagnosed incident cases of NSCLC by sex, N, ages ≥18 years, 2022
Figure 17: 8MM, diagnosed incident cases of NSCLC by histological subtype, N, both sexes, ages ≥18 years, 2022
Figure 18: 8MM, five-year diagnosed prevalent cases of NSCLC, N, both sexes, ≥18 years, 2022

$3,995
$7,990
$11,985

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings